Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene Symbol ARID1B
Synonyms 6A3-5 | BAF250B | BRIGHT | CSS1 | DAN15 | ELD/OSA1 | MRD12 | OSA2 | P250R | SMARCF2
Gene Description ARID1B, AT-rich interactive domain-containing protein 1B, is a member of the cBaF subunit (PMID: 32303701) of the SWI/SNF chromatin remodeling complex and is involved in cell-cycle activation (PMID: 15170388) and plays a role in neurodevelopment (PMID: 25674384). ARID1B mutations have been identified in several tumor types including, melanoma, gastric, colorectal, liver, neuroblastoma (PMID: 28521285), and pancreatic (PMID: 27737960) and decreased expression has been observed in ovarian clear cell carcinoma (PMID: 29890703).
NCBI Gene ID Chromosome Map Location Canonical Transcript Gene Role
57492 6 6q25.3 NM_017519 Tumor suppressor (PMID: 30606230)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1B dec exp Advanced Solid Tumor predicted - sensitive Cisplatin Preclinical - Cell culture Emerging In a preclinical study, siRNA knockdown of ARID1B in cultured tumor cells resulted in increased sensitivity to Platinol (cisplatin), suggesting that tumors with ARID1B loss or inactivation may have increased response to DNA damaging agents (PMID: 24788099). 24788099
ARID1B inact mut melanoma not predictive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with melanoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.70 (p=0.192, n=86) and 1.02 (p=0.939, n=192), respectively (PMID: 32321774). 32321774
ARID1B inact mut transitional cell carcinoma not predictive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with transitional cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 1.44 (p=0.34, n=56) and 0.82 (p=0.559, n=93), respectively (PMID: 32321774). 32321774
ARID1B inact mut head and neck squamous cell carcinoma not predictive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with head and neck squamous cell carcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.74 (p=0.631, n=31) and 0.76 (p=0.622, n=68), respectively (PMID: 32321774). 32321774
ARID1B inact mut colorectal adenocarcinoma unknown unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, correlated with improved survival in one cohort of patients with colorectal adenocarcinoma treated with systemic immune checkpoint inhibitors but not the other, with adjusted HRs for overall survival of 0.30 (p=0.03, n=35) and 0.56 (p=0.244, n=63), respectively (PMID: 32321774). 32321774
ARID1B inact mut gastroesophageal adenocarcinoma not predictive unspecified immune checkpoint inhibitor Clinical Study - Cohort Actionable In a retrospective analysis, somatic loss-of-function mutations in the genes of the mSWI/SNF complex, including ARID1B, did not correlate with improved survival in 2 separate cohorts of patients with gastroesophageal adenocarcinoma treated with systemic immune checkpoint inhibitors, with adjusted HRs for overall survival of 0.70 (p=0.403, n=66) and 0.46 (p=0.071, n=59), respectively (PMID: 32321774). 32321774
ARID1B Q127_Q131del IDH1 R132L cholangiocarcinoma no benefit Niraparib Preclinical - Patient cell culture Actionable In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Zejula (niraparib) in culture (PMID: 36374558). 36374558
ARID1B Q127_Q131del IDH1 R132L cholangiocarcinoma no benefit Olaparib Preclinical - Pdx & cell culture Actionable In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Lynparza (olaparib) in culture and did not inhibit tumor growth in the patient-derived xenograft model (PMID: 36374558). 36374558
ARID1B Q127_Q131del IDH1 R132L cholangiocarcinoma no benefit Pamiparib Preclinical - Pdx & cell culture Actionable In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Pamiparib (BGB-290) in culture and did not inhibit tumor growth in the patient-derived xenograft (PDX) model (PMID: 36374558). 36374558